Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
Protocol ID
CFZ2008 / 20140106
Disease (Sub Disease)
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC
Sponsor
Amgen
Collaborators
Therapeutic Advances in Childhood Leukemia & Lymphoma
Innovative Therapies For Children with Cancer Consortium
Trial Status
Open
Sites
Queensland Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Month to 21 Years
International registry ID's
NCT02303821
Back to Registry
Study Title Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
Protocol ID CFZ2008 / 20140106
Disease (Sub Disease) Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage Relapse/refractory
Location NSW / QLD / VIC
Sponsor Amgen
Collaborators Therapeutic Advances in Childhood Leukemia & Lymphoma/ Innovative Therapies For Children with Cancer Consortium/
Links https://clinicaltrials.gov/ct2/show/NCT02303821
Trial Status Open
Trial Open Date 10/09/2015
Sites Queensland Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 1 Month to 21 Years
International registry ID's NCT02303821